XKRX:314130 (Korea, South)  
Genome & Co logo

Genome & Co

₩ 20300.00 (-1.93%) Aug 19
P/E:
At Loss
P/B:
3.15
Market Cap:
₩ 291.17B ($ 217.73M)
Enterprise V:
₩ 200.94B ($ 150.25M)
Volume:
56.05K
Avg Vol (2M):
84.50K
Volume:
56.05K
Market Cap ₩:
291.17B
Market Cap $:
217.73M
PE Ratio:
At Loss
Avg Vol (2-Month):
84.50K
Enterprise Value ₩:
200.94B
Enterprise Value $:
150.25M
PB Ratio:
3.15
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Genome & Co
Innovalley A-801, Pangyo-ro 253, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
Description
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.
Name Current Vs Industry Vs History
Cash-To-Debt 13.07
Equity-to-Asset 0.57
Debt-to-Equity 0.08
Debt-to-EBITDA -0.21
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.14
Distress
Grey
Safe
Beneish M-Score 11.62
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 39.04
9-Day RSI 48.14
14-Day RSI 51.34
6-1 Month Momentum % -27.17
12-1 Month Momentum % -52.03

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.1
Quick Ratio 9.93
Cash Ratio 9.5
Days Inventory 126
Days Sales Outstanding 50.17
Days Payable 38.69

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -22.2

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 38.31
Operating Margin % -1263.42
Net Margin % -1183.93
ROE % -37.29
ROA % -28.92
ROIC % -118.82
ROC (Joel Greenblatt) % -377.59
ROCE % -32.33

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₩) 3,063.364
EPS (TTM) (₩) -2661
Beta 1.64
Volatility % 65.6
14-Day RSI 51.34
14-Day ATR (₩) 1033.215785
20-Day SMA (₩) 20055
12-1 Month Momentum % -52.03
52-Week Range (₩) 15350 - 57600
Shares Outstanding (Mil) 14.07

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Genome & Co Filings

Document Form Filing Date
No Filing Data